← Back to Screener
Eledon Pharmaceuticals, Inc. Common Stock (ELDN)
Price$3.98
Favorite Metrics
Price vs S&P 500 (26W)36.51%
Price vs S&P 500 (4W)28.70%
Market Capitalization$301.89M
All Metrics
Book Value / Share (Quarterly)$1.81
P/TBV (Annual)1.09x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.83
Price vs S&P 500 (YTD)159.44%
EPS (TTM)$-0.56
10-Day Avg Trading Volume1.80M
EPS Excl Extra (TTM)$-0.56
EPS (Annual)$-0.56
ROI (Annual)-33.35%
Cash / Share (Quarterly)$1.77
ROA (Last FY)-26.99%
EBITD / Share (TTM)$-0.56
ROE (5Y Avg)-65.84%
Cash Flow / Share (Annual)$-0.83
P/B Ratio2.21x
P/B Ratio (Quarterly)0.83x
Net Income / Employee (Annual)$-1
ROA (TTM)-30.16%
EV / EBITDA (TTM)18.25x
EPS Incl Extra (Annual)$-0.56
Current Ratio (Annual)7.40x
Quick Ratio (Quarterly)7.30x
3-Month Avg Trading Volume1.09M
52-Week Price Return32.67%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.38
52-Week High$4.60
EPS Excl Extra (Annual)$-0.56
Tangible BV CAGR (5Y)-7.98%
26-Week Price Return45.26%
Quick Ratio (Annual)7.30x
13-Week Price Return96.06%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.40x
Enterprise Value$279.082
Book Value / Share Growth (5Y)-32.07%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.77
3-Month Return Std Dev70.15%
Net Income / Employee (TTM)$-1
ROE (Last FY)-33.35%
EPS Basic Excl Extra (Annual)$-0.56
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.56
ROI (TTM)-40.69%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.38
Price vs S&P 500 (52W)-2.43%
Year-to-Date Return163.58%
5-Day Price Return23.60%
EPS Normalized (Annual)$-0.56
ROA (5Y Avg)-58.65%
Month-to-Date Return29.22%
Cash Flow / Share (TTM)$-2.83
EBITD / Share (Annual)$-0.56
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-65.84%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.56
P/TBV (Quarterly)1.09x
P/B Ratio (Annual)0.83x
Book Value / Share (Annual)$1.81
Price vs S&P 500 (13W)93.19%
Beta1.07x
Revenue / Share (TTM)$0.00
ROE (TTM)-40.69%
52-Week Low$1.35
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.23
4.23
4.23
4.23
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ELDNEledon Pharmaceuticals, Inc. Common Stock | — | — | — | — | $3.98 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
Eledon Pharmaceuticals is a clinical-stage biotech company developing tegoprubart, an anti-CD40L antibody targeting a well-validated pathway with broad therapeutic potential. The company is pursuing applications across transplantation, autoimmune diseases, and ALS, addressing significant unmet medical needs in each indication.